Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Sales (2019 - 2025)

Historic Return on Sales for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to 0.51%.

  • Keros Therapeutics' Return on Sales rose 1359700.0% to 0.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year increase of 2887100.0%. This contributed to the annual value of 52.78% for FY2024, which is 9604200.0% up from last year.
  • Keros Therapeutics' Return on Sales amounted to 0.51% in Q3 2025, which was up 1359700.0% from 1.69% recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Return on Sales registered a high of 15885.0% during Q1 2021, and its lowest value of 5410.0% during Q3 2023.
  • Over the past 5 years, Keros Therapeutics' median Return on Sales value was 5.82% (recorded in 2022), while the average stood at 438.53%.
  • Per our database at Business Quant, Keros Therapeutics' Return on Sales soared by 158878100bps in 2021 and then tumbled by -158863400bps in 2022.
  • Quarter analysis of 5 years shows Keros Therapeutics' Return on Sales stood at 0.39% in 2021, then plummeted by -1400bps to 5.82% in 2022, then plummeted by -5486bps to 324.86% in 2023, then skyrocketed by 95bps to 15.13% in 2024, then soared by 97bps to 0.51% in 2025.
  • Its Return on Sales was 0.51% in Q3 2025, compared to 1.69% in Q2 2025 and 0.7% in Q1 2025.